{
  "docId": "019de072-fb61-72df-84cb-88e5545aef17",
  "docSlug": "ab8c2c2aa3a78f1c4e59d8338668e5e1",
  "documentTitle": "Genetron | Results Presentation Deck | 29 slides",
  "authorId": "genetron",
  "authorName": "Genetron",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 29,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "key_messages",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes a scatter plot comparing Seq-MRD and FCM results, and a 2x2 contingency table for diagnostic performance.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-fb61-72df-84cb-88e5545aef17/12",
  "deckHref": "/decks/019de072-fb61-72df-84cb-88e5545aef17",
  "deckJsonHref": "/decks/019de072-fb61-72df-84cb-88e5545aef17.json",
  "deckAnchorHref": "/decks/019de072-fb61-72df-84cb-88e5545aef17#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.7,
        "x": 0.15,
        "y": 0.12
      },
      "kind": "callout",
      "text": "Enabled by One-step Seq + fully automated bioinformatics solutions",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b378dba6-46ec-4782-88fc-a3f6220c94eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.32,
        "y": 0.73
      },
      "kind": "callout",
      "text": "Initiated commercialization in China",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c74d92e5-81e9-4999-bd8b-473a1c99cce9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.7,
        "x": 0.15,
        "y": 0.21
      },
      "kind": "callout",
      "text": "Higher sensitivity compared with FCM",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce7669ed-8c42-43f0-9c3e-7b1f6f985bd1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.4,
        "x": 0.55,
        "y": 0.28
      },
      "kind": "chart",
      "text": null,
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4f1600c-0565-4c6a-a784-4cbc02133c28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.07,
        "y": 0.45
      },
      "kind": "list",
      "text": "Based on validation data from 128 clinically confirmed patients' samples... The positive detection results of traditional flow cytometry (FCM) and Seq-MRD were highly consistent.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39d119a5-dd1a-4ea3-a77e-460d62aa0237",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.07,
        "y": 0.3
      },
      "kind": "list",
      "text": "In the performance verification test for ALL, CLL and MM, when loading 20µg sample: For ALL and MM sample, the LOD is 6.5x10^-7; For CLL sample, the LOD is 9.75x10^-7.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d3e37cf-f754-49b3-a9ab-d183ca2c27cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.07,
        "y": 0.8
      },
      "kind": "list",
      "text": "Exclusively collaborating with Fosun Pharma in hematologic-focused hospitals and clinics in China. Fosun has 1,500 sales reps to sell innovative drugs that target hematologic and lymphoid malignancies, and solid tumors.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fc25e26-7467-410c-8072-b2f45f16669b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.07,
        "y": 0.6
      },
      "kind": "list",
      "text": "Among them, 10 cases were detected MRD positive by Seq-MRD but negative by FCM, which reflected the higher sensitivity of Seq-MRD.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a2719d3-2350-4abc-9173-2792b6894755",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.06,
        "y": 0.91
      },
      "kind": "subtitle",
      "text": "ALL: acute lymphoblastic leukemia MM: multiple myeloma CLL: chronic lymphoid leukemia",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f9ab6bb-8c07-4f88-8496-49151c9afa9f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.5,
        "y": 0.6
      },
      "kind": "table",
      "text": null,
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5dd12842-f467-40f7-a911-e086611ac17a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Seq-MRD® for Hematologic Cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c889264-2934-492f-894d-8526d3a77ab1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "5e99a57f-7e9a-4495-b2d9-0586603ba015",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document proposes solutions, such as the Advantage of Mutation Capsule in Solid-tumor MRD and Seq-MRD offers higher sensitivity.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}